Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Soleno Therapeutics, Inc. - Common Stock (NQ:SLNO)

49.85 -0.10 (-0.20%)
Streaming Delayed Price Updated: 12:03 PM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Soleno Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet? ↗
Soleno just turned profitable for the first time—right as a major fund made its move. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Bragar Eagel & Squire, P.C. Encourages Agilon, Soleno, Avita, and Coty Investors to Contact the Firm Regarding Ongoing Investigations
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Encourages Agilon, Soleno, Avita, and Coty Investors to Contact the Firm Regarding Ongoing Investigations
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Soleno Therapeutics Unveils $100 Million Buyback Citing 'Underappreciated' Future ↗
Soleno Therapeutics (SLNO) approved $100M share repurchase program & entered ASR agreement with Jefferies LLC to buy back its stock. 
Via Benzinga
News headline image
PubMatic Posts Upbeat Q3 Results, Joins Energy Vault, RealReal And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
SLNO INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Soleno Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Agilon, Soleno, Avita, and Coty and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
These stocks are moving in today's session ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Wednesday's session: gap up and gap down stocks ↗
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Super Micro Computer Posts Downbeat Q1 Results, Joins Pinterest, Axon Enterprise And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
These stocks that are showing activity before the opening bell on Wednesday. ↗
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Teradata Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
What's going on in today's after hours session ↗
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SLNO
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
SOLENO (SLNO) REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into Soleno Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
SOLENO INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short ↗
Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales in 2025 and highlights a strong pipeline outlook. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.